Dr. Sabrina Paganoni, Massachusetts General Hospital, will discuss CENTAUR, a trial for people with ALS. CENTAUR ("Combination of Phenylbutyrate and Tauroursodeoxycholic Acid") is a Phase 2 trial testing the efficacy and safety of AMX0035 for the treatment of ALS as well as its impact on several disease biomarkers. CENTAUR is expected to enroll 132 participants nationwide.
